ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Nuvation Bio Announces FDA Clearance of Investigational NDA for NUV-422 for the Treatment of Advanced Breast Cancer
December 09, 2021Nuvation Bio Inc. announced that the FDA has cleared its investigational new drug (IND) application to evaluate NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of advanced breast cancer. The FDA accepted the Company's first ... -
Nuvation Bio Granted Orphan Drug Designation for NUV-422 for Malignant Gliomas
March 19, 2021Nuvation Bio announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of patients with malignant gliomas.
Pharma Sources Insight January 2025
